HealthCare Global Revenue Surges, Profit Tumbles Amidst Rising Debt Concerns

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
HealthCare Global Revenue Surges, Profit Tumbles Amidst Rising Debt Concerns
Overview

HealthCare Global Enterprises (HCG) reported a 13% YoY revenue jump to INR 6,331 million in Q3FY26, with EBITDA up 20%. However, Adjusted PAT declined sharply to INR 6 million from INR 70 million a year ago, driven by higher depreciation, interest costs, and a prior-year corporate restructuring benefit. Net debt rose to INR 16,337 million, and interest cover fell to a critical ~1.28x. The North Bangalore Greenfield Hospital is slated for Q4FY26 operation.

HealthCare Global Enterprises (HCG) Q3FY26 Earnings Analysis: Growth Amidst Profit Pressure

HCG has posted a mixed set of results for the quarter and nine months ended December 31, 2025 (Q3 & 9MFY26), showcasing robust top-line expansion contrasted with a significant hit to profitability and increasing debt levels.

📉 The Financial Deep Dive

The Numbers:
For Q3FY26, HCG reported a 13% year-on-year (YoY) revenue growth, reaching INR 6,331 million from INR 5,586 million in Q3FY25. This growth was broad-based, with the West cluster leading at 17% YoY. Adjusted EBITDA saw a healthy 20% YoY increase to INR 1,108 million. Consequently, the Adjusted EBITDA margin improved by 98 basis points to 17.5%.

However, the bottom line painted a concerning picture. Adjusted Profit After Tax (PAT) declined drastically to INR 6 million in Q3FY26, down from INR 70 million in the prior year. Reported EPS turned negative at (0.7) compared to 0.5 in Q3FY25. This profit decline was primarily attributed to higher depreciation and interest expenses from recent growth investments and acquisitions, compounded by a one-off benefit from corporate restructuring in Q3 FY25.

For the nine months ended December 31, 2025 (9MFY26), revenue grew 15% YoY to INR 18,931 million, and Adjusted EBITDA rose 20% YoY to INR 3,458 million, with margins expanding by 60 basis points to 18.3%. However, Adjusted PAT fell to INR 216 million from INR 371 million YoY.

The Quality:
While EBITDA margins expanded, indicating operational efficiency gains, the substantial drop in PAT despite revenue and EBITDA growth highlights significant cost pressures and financial burdens. Cash Flow vs. Net Profit analysis is not readily available in the provided data, but the increasing debt and finance costs are points of concern.

🚩 Risks & Outlook

Specific Risks:
A major red flag is the mounting net debt, which stood at INR 16,337 million as of December 31, 2025. The finance cost for 9MFY26 was INR 1,339 million against an EBIT of INR 1,713 million, resulting in a critically low interest cover ratio of approximately 1.28x. This indicates HCG's limited ability to service its debt obligations from its operating profits, posing a significant financial risk.

The Forward View:
Despite the financial headwinds, HCG is investing in growth. Capital expenditure increased to INR 2,227 million in 9MFY26. The company is on track to open its North Bangalore Greenfield Hospital, equipped with advanced MR-LINAC technology, by the end of Q4FY26. This expansion is expected to be a key growth driver, provided the company can manage its debt and improve profitability.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.